

1 **Title page**

2 Common pathogenic mechanisms for COVID-19 and differentiated thyroid cancer: a
3 proteomic analysis

4
5 Hanqing Liu ^{1,*}, Jiayi Wang ^{1,*}, Dan Yang ^{2,#}, Chuang Chen ^{1,#}

6
7 Addresses

8 ¹ Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan,
9 430060, Hubei, People's Republic of China.

10 ² Department of Cardiology, the Second Affiliated Hospital of Chongqing Medical University,
11 Chongqing 400010, People's Republic of China.

12
13 * The two authors contributed equally to the work

14
15 # Correspondence:

16 Prof. Chuang Chen,

17 Department of Thyroid and Breast Surgery,

18 Renmin Hospital of Wuhan University,

19 Wuhan University at Jiefang Road 238, Wuhan 430060, RP China.

20 Tel: +86 27 88041911; Fax: +86 27 88041911. (Email: chenc2469@163.com)

21

22 Dr. Dan Yang,

23 Department of Cardiology,

24 The Second Affiliated Hospital of Chongqing Medical University,

25 Chongqing Medical University, Chongqing 400010, RP China.

26 Tel: +86 023 68811360; Fax: +86 023 68811360. (Email: DrYang@hospital.cqmu.edu.cn)

27

28

29 **Abstract and keywords**

30 Abstract

31 Background: Previous studies have proved that viral infection might have potential
32 associations with differentiated thyroid cancer. COVID-19 has spread to hundreds of millions
33 of individuals since Dec 2019. This study aimed to investigate the common pathogenic
34 mechanisms of differentiated thyroid cancer and SARS-CoV-2 infection in thyroid tissues.

35 Methods: The proteomic profiles of COVID-19 and differentiated thyroid cancer were
36 downloaded from iProX database and were analyzed for differentially expressed proteins.
37 After the common proteins were identified using the Venn diagram, gene ontology and
38 pathway enrichment analysis were performed. Subsequently, a protein-protein interaction
39 network was constructed and hub genes were identified with eight algorithms. The diagnostic
40 performance of hub genes was tested with the receiver operator characteristics curve. The
41 associations between hub genes and diseases were evaluated with the Comparative
42 Toxicogenomics Database.

43 Results: Forty-nine common differentially expressed proteins were identified. Functional
44 analysis revealed that the metabolism and transport of lipid and cholesterol and coagulation
45 process were the main common biological activities affected by the two diseases. In addition,
46 twelve genes, including AGT, AHSG, APOA2, APOM, C3, GC, ITIH2, KNG1, SERPINA1,
47 SERPINC1, TF and TTR, were identified as the hub genes. These genes could serve as
48 diagnostic markers for COVID-19 and differentiated thyroid cancers.

49 Conclusion: The current study revealed common pathogenic mechanisms of COVID-19 and
50 differentiated thyroid cancer. The concomitant infection of SARS-CoV-2 might exert adverse
51 effects on patients with thyroid cancers.

52

53 Keywords: DTC, coronavirus disease 2019, SARS-CoV-2, bioinformatics

54

55

56 **1 Introduction**

57 Thyroid cancer is the most common endocrine malignancy all over the world (1). Its
58 incidence has doubled since the mid-1990s (2, 3). Although thyroid cancer consists of several
59 histopathological types, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC)
60 account for more than 80% of total cases. PTC and FTC are also categorized as differentiated
61 thyroid cancer (DTC) in contrast with poorly differentiated and anaplastic thyroid cancers.
62 Notably, DTC contributes to the majority of incidence elevation (4). While the incidence of
63 other histopathological subtypes remains almost unaltered, the incidence of DTC increased by
64 300% since 1975 (5). The elevation may be explained by both increasing exposure to risk
65 factors and the application of ultrasound devices with high resolution.

66 The risk factors for thyroid cancers are various, including radiation, iodine deficiency,
67 genetic susceptibility, etc. More recently, the association between thyroid cancer and viral
68 infection has been noticed. Epstein-Barr virus is a well-known human tumor virus associated
69 with multiple malignancies, including nasopharyngeal carcinoma, Hodgkin's lymphoma and
70 Burkitt's lymphoma. A retrospective clinical study using *in situ* hybridization showed that the
71 detection of Epstein-Barr virus (EBV) was significantly higher in thyroid cancer tissues
72 compared with paired adjacent normal tissues (6). Similar results were verified with serologic
73 assays in another study (7). In addition, the potential link between hepatitis C virus and
74 thyroid cancer has been revealed. A higher prevalence of chronic hepatitis was found in
75 patients with thyroid cancers (8). Similar phenomena were also found in patients infected
76 with hepatitis B virus (9, 10), human erythrovirus B19 (11, 12), cytomegalovirus (13), and
77 human T-cell lymphotropic virus (14). Of interest, these viruses are also related to
78 autoimmune thyroiditis (15). The carcinogenetic mechanism of these viruses, if exists, is most
79 likely to be chronic inflammation. Some virus proteins, such as latent membrane protein
80 released by EBV, can exert effects on cell cycle-related intracellular proteins. Inferably, viral
81 oncogene may also be a potential mechanism in the carcinogenesis of thyroid cancer.

82 Since the first case was reported in Wuhan, China in Dec 2019, coronavirus disease 2019
83 (COVID-19) has spread to 228 countries and territories. More than six hundred million cases
84 were confirmed and its mortality is approximately 1% (16). Undoubtedly, the real incidence is
85 much higher than the reported number since nucleic acid tests and antigen assays are not
86 performed in all suspected patients. The pathogen of COVID-19 is severe acute respiratory
87 syndrome coronavirus 2 (SARS-CoV-2). The new coronavirus can invade peripheral tissue
88 cells via the angiotensin-converting enzyme 2 (ACE2) and cause multiple organ dysfunctions,
89 including lung, kidney and heart (17). Direct viral infection, cytokine storm, down-regulation
90 of ACE2 and endothelial cell damage are supposed to be the pathogenic mechanisms (18-20).

91 Of interest, current evidences suggest that potential linkages may exist between thyroid
92 cancer and COVID-19. A multicenter cohort study in Los Angeles revealed a positive
93 correlation between comorbid conditions and risk of hospitalization from SARS-CoV-2
94 infection in thyroid cancer patients (21). Another retrospective study revealed a small but
95 significant elevation of DTC after the outbreak of the pandemic, although the results were
96 hard to explain and confounding factors needed to be explored (22). Autoimmune thyroid
97 diseases are known to increase the risk of thyroid cancer. Previous reports have shown that

98 the relapse or new diagnosis of autoimmune thyroid diseases could be triggered within one
99 month after SARS-CoV-2 infection (23). Some researchers have assumed that thyroid
100 inflammation could be induced by COVID-19-related immune response (24). Since the ACE2
101 expression levels are higher in thyroid tissue in comparison with lung (25), the coronavirus
102 might damage normal thyroid tissues and subsequently induce carcinogenesis. Currently, little
103 is known about the association between COVID-19 and DTC from a molecular aspect.

104 The aim of this study is to evaluate the potential common molecular mechanisms for DTC
105 and COVID-19 using bioinformatic tools.

106

107 **2 Materials and methods**

108 2.1 Data acquisition

109 Two proteomic expression profiles were selected and downloaded from iProX database
110 (Figure 1) (26). iProX database is a public platform for collecting and sharing proteomics
111 datasets. The two proteomic datasets were both released by Guo's lab at Westlake University
112 (27, 28). The tissue biopsy samples were processed using the pressure cycling technique
113 protocol to separate small amounts of components. Subsequently, data-independent
114 acquisition mass spectrometry was used to analyze the prepared samples at high throughput.
115 The IPX0002393000 dataset displayed the proteomic profiles of various organs in patients
116 with COVID-19 (Table 1). An amount of 15 thyroid samples from the autopsy of infected
117 patients and 15 from non-infected patients were extracted. The IPX0001444000 dataset
118 included 1161 samples of various thyroid diseases, including differentiated thyroid cancer
119 (DTC), benign thyroid diseases and normal thyroid tissues (NT). Two hundred and
120 twenty-three samples of differentiated thyroid cancer or normal thyroid tissues in the
121 discovery subgroup were collected for subsequent analysis.

122

123 2.2 Identification of DEPs

124 Expression profiles were inputted into R project (v4.2.0). The clinical information was
125 collected from the two datasets for sample classification. Samples of irrelevant diseases were
126 excluded from the expression matrices. Missing data were imputed using the k-nearest
127 neighbors algorithm in *DMwR2* package. Since technical replicates for each sample were set
128 and batch effects were minimized at the batch design level, the robust multi-array
129 normalization was not conducted so as not to eliminate the true difference (Sup figure 1).
130 UniProtKB AC/IDs were converted to general gene symbols via the online tool UniProt (29).
131 When multiple protein IDs corresponded to one gene symbol, the medians were calculated.
132 The Bayesian method in the *limma* R package was used to identify the differentially
133 expressed proteins (DEPs) in two comparisons (COVID-19 vs. not infected, and DTC vs. NT).
134 *P*-values were adjusted using the Benjamini-Hochberg method. Fold-changes (FCs) were

135 calculated with the false-discovery rate procedure. DTC-DEGs with $|\log_2\text{-FC}| > 1$ and $p < 0.01$
136 were selected. COVID-19-DEGs were filtered according to the criteria $|\log_2\text{-FC}| > 0.5$ and p
137 < 0.01 . The Venn diagram of DEGs was constructed with SangerBox (v3.0) (30) to identify
138 the overlapping DEPs. Heatmaps were constructed to visualize the common DEPs in the two
139 expression profiles.
140

141 2.3 Gene ontology and pathway enrichment analysis

142 Gene ontology (GO) annotation and pathway analysis were performed with three online
143 tools, namely, DAVID (v2022q3), AmiGO (v2.5.17) and Reactome (v83) (31-33). The GO
144 enrichment analysis included three categories: biological process (BP), molecular function
145 (MF) and cellular component (CC). The results of GO enrichment were verified by the
146 AmiGO database. The Kyoto Encyclopedia of Genes and Genome (KEGG) was used to
147 analyze the biological pathways in which the shared DEPs were mainly involved. The
148 Reactome database was used to verify the results of KEGG. P -value < 0.05 was deemed as the
149 threshold for the GO enrichment analysis and the pathway analysis. The results were
150 visualized using bubble charts.
151

152 2.4 Construction of PPI network and identification of hub genes

153 The protein-protein interactions (PPIs) of shared DEPs were analyzed with an online tool,
154 STRING (v11.5) (34). PPIs with interaction scores > 0.4 was considered significant. The
155 results from STRING database were then imported into Cytoscape (v3.9.1) for visualization
156 of the PPIs. A plug-in software, CytoHubba (35), was used to identify the 20 hub genes with
157 eight algorithms (degree, edge percolated component, maximum neighborhood component,
158 maximal clique centrality, closeness, radiality, betweenness, and stress). The intersected hub
159 genes were identified using the upset plot. GeneMania were utilized to construct the
160 co-expression network of intersected hub genes and their related genes (36).

161 Receiver operator characteristics (ROC) curve and the area under the curve (AUC) were
162 utilized to evaluate the diagnostic accuracy of hub genes on COVID-19 and the DTC.
163

164 2.5 Associations between hub genes and diseases

165 The associations between the twelve hub genes and related diseases were analyzed using the
166 Comparative Toxicogenomics Database (CTD) (37). CTD is an innovative ecosystem that
167 relates the toxicological information of genes to diseases. Diseases categorized as cancer,
168 respiratory tract disease and viral disease were searched. Bar charts were produced to display
169 the associations between hub genes and COVID-19 and DTC.
170

171 3 Results

172 3.1 Identification of DEPs in COVID-19 and DTC

173 A total of 18373 UniProt IDs were converted to 11615 and 6681 gene symbols for the two
174 datasets (IPX0001444000 and IPX0002393000), respectively. By comparing the thyroid
175 samples from patients infected with COVID-19 and those not infected, 137 proteins were
176 confirmed as the COVID-19-DEPs. In addition, 1613 proteins were found to be DTC-DEPs
177 by comparing DTC samples with NTs (Figure 2a&b). The Venn diagram depicted the shared
178 DEPs of two comparisons. Forty-nine common DEPs were identified (Figure 2c &
179 Supplementary data). The expressions of common DEPs in two matrices were displayed with
180 heatmaps (Sup figure 2a&b).

181

182 3.2 GO annotation and functional analysis of shared DEPs

183 GO annotations were performed with the DAVID database. A total of 64 GO terms with
184 p -value <0.05 were revealed to be associated with the common DEPs (Figure 3a-c). The most
185 enriched BPs were triglyceride-rich lipoprotein particle remodeling, negative regulation of
186 cholesterol transport and high-density lipoprotein particle clearance. The most enriched CCs
187 were focused on lipoproteins, including spherical high-density, very-low-density and
188 high-density lipoprotein particles. In addition, enzyme inhibitor activity, including lipase,
189 endopeptidase and cysteine-type endopeptidase, ranked top among the enriched MFs. The
190 fold enrichments (FEs) were >30 for the MFs, BPs and CCs mentioned above. The above
191 results were verified with AmiGO database (Supplementary data).

192 The results of Reactome pathway enrichment analysis were depicted in Figure 3d. The
193 pathways that were most related to common DEPs were chylomicron assembly (FE=44.43),
194 chylomicron remodeling (FE=36.59) and intrinsic pathway of fibrin clot formation
195 (FE=35.89). The pathway analysis from KEGG provided additional information
196 (Supplementary data).

197

198 3.3 PPI network construction and identification of hub genes

199 The PPI network included 38 nodes and 149 edges (Figure 4). Eleven common DEPs were
200 excluded due to no connectivity to other genes. Redder color indicated higher connectivity to
201 other genes. Of note, serpin family A member 1 (SERPINA1) was associated with 20 genes in
202 the network.

203 The top twenty hub gene lists generated by the eight algorithms in CytoHubba were
204 collected (Figure 5a). The intersection of the upset chart identified twelve final hub genes,
205 including AGT, AHSG, APOA2, APOM, C3, GC, ITIH2, KNG1, SERPINA1, SERPINC1,

206 TF and TTR. A complex gene interaction network was constructed with the GeneMania
207 database (Figure 5b). Co-expression contributed to the most interactions in the network
208 (54.09%), followed by co-localizations and physical interactions (21.27% and 19.85%,
209 respectively). The remodeling of protein-lipid complex, plasma lipoprotein particle and
210 protein-containing complex were biological activities most likely associated with hub genes.

211 GO annotations and pathway enrichment analysis were conducted based on the twelve hub
212 genes (Sup figure 3a&b). The top five GO terms that related to the hub genes were
213 high-density lipoprotein particle clearance, spherical high-density lipoprotein particle,
214 positive regulation of CoA-transferase activity, positive regulation of cholesterol esterification
215 and high-density lipoprotein particle assembly. After excluding pathways which only one hub
216 gene was involved, Reactome database revealed that intrinsic pathway of fibrin clot formation,
217 post-translational protein phosphorylation and regulation of insulin-like growth factor
218 transport and uptake by insulin-like growth factor binding proteins were the most enriched
219 pathways related to hub genes.

220

221 3.4 Diagnostic accuracy of hub genes

222 ROC curves were used to test the diagnostic performance of twelve hub genes (Figure
223 6a&b). In the COVID-19 dataset, apolipoprotein A2 (APOA2) and serpin family C member 1
224 (SERPINC1) exhibited the highest diagnostic efficiency (AUC=1.00 for two genes), followed
225 by complement C3 (C3) and inter-alpha-trypsin inhibitor heavy chain 2 (ITIH2) (AUC=0.96
226 for two genes). In contrast, transferrin (TF) exhibited the best performance (AUC=0.80) in the
227 DTC dataset, followed by transthyretin (TTR, AUC=0.78), alpha 2-Heremans Schmidt
228 glycoprotein (AHSG, AUC=0.78) and vitamin D binding protein (GC, AUC=0.77).

229

230 3.5 Associations between hub genes and diseases

231 Ten among the twelve hub genes were shown to have potential interactions with COVID-19
232 (Figure 7). Notably, direct evidence has proved that angiotensinogen (AGT) participated in
233 the infection of SARS-CoV-2. Besides, C3 and kininogen 1 (KNG1) also had potential
234 interactions with COVID-19. The associations of hub genes and differentiated thyroid cancers
235 were divided into three categories (PTC, FTC and thyroid neoplasms). Transthyretin (TTR),
236 C3, and apolipoprotein M (APOM) exhibited associations with thyroid cancers in all three
237 categories. In addition, ITIH2 had the strongest connection (interference score=8.00) with
238 FTC while TF connected with thyroid neoplasms (interference score=38.25).

239

240 4 Discussion

241 In this study, twelve hub genes were identified from 49 common DEPs, including AGT,

242 AHSB, APOA2, APOM, C3, GC, ITIH2, KNG1, SERPINA1, SERPINC1, TF and TTR. GO
243 annotations and pathway enrichment analysis revealed several biological activities that might
244 involve in the interaction of COVID-19 and DTC. Briefly, the *in vivo* transport and
245 metabolism of lipid and cholesterol are supposed to be the most likely common pathogenic
246 mechanism in COVID-19 and DTC. In addition, vasodilation and coagulation process may
247 also play roles, whereas chronic inflammation and immune response showed little effects.

248 The pathogenic effects of COVID-19 on thyroid gland have been gradually noticed since the
249 outbreak of the pandemic in Wuhan. In March 2020, a retrospective clinical study in Wuhan
250 evaluated the clinical and laboratory data of 274 patient infected with the new coronavirus
251 disease (38). In comparison with those who finally recovered from COVID-19, deceased
252 cases presented with lower levels of serum thyroxine and triiodothyronine. Confusingly, the
253 thyroid stimulation hormones were also decreased in these patients. Subsequent studies
254 verified that ACE2 is the main host cell receptor for SARS-CoV-2 (39). Taken that ACE2 is
255 widely expressed in multiple organs, including thyroid and pituitary (25), we may
256 hypothesized that the hypothalamus-pituitary-thyroid axis is impaired during the infection. In
257 comparison with healthy controls, infected patients were more likely to develop
258 hyperthyroidism, as revealed by a retrospective study (40). Another study recruited
259 COVID-19 patients in the intensive care units (41). The incidence of subacute and atypical
260 thyroiditis was much higher in those with high intensity of care (10% vs. 0.5%). Besides,
261 Grave's disease could also be triggered by SARS-CoV-2 infection in patients with or without
262 a previous Grave's disease history (42, 43). Direct viral infection and hyperinflammatory state
263 by COVID-19 are both believed to induce thyroid autoimmune disorders.

264 Although numerous evidences have proven the damage of coronavirus on thyroid tissue, the
265 linkage between thyroid cancer and COVID-19 is unclear. Our previous study in Wuhan
266 showed that thyroid cancer behaviors were generally more aggressive compared to those
267 before the pandemic (22). More cases with multiple lesions, extrathyroidal extension and
268 lymph node metastasis were discovered. A multicenter cohort study in Los Angeles suggested
269 that comorbidities and old age are hazard factors for patients diagnosed with both thyroid
270 cancer and COVID-19 (21). Another nationwide study evaluated the COVID-19 outcomes
271 and mortality in thyroid cancer patients with COVID-19 infection (44). No elevation in
272 mortality and morbidity was revealed. The conclusions were verified by a multicenter cohort
273 study conducted in South Korea (45). Nevertheless, considering the fact that a small
274 proportion of patients receive tyrosine kinase inhibitor therapy or have distant metastasis, it is
275 reasonable to anticipate that these patients are at high risk for complications of COVID-19.

276 Among the twelve hub genes identified, AGT is the gene most related to COVID-19. AGT
277 gene encodes for the angiotensinogen precursor, which is quickly converted to angiotensin I
278 with the regulation of blood pressure and renin. Two retrospective studies drew the same
279 conclusion that AGT rs699 C>T single-nucleotide polymorphism could increase the risk and
280 severity of COVID-19 (46, 47). Another study collected serum samples from 45 infected
281 patients and 34 controls (48). Proteomic analysis revealed that AGT was elevated in almost all
282 infected patients and its serum concentration was strongly indicative of disease severity.
283 Taken that ACE2 is the key factor in the internalization of SARS-CoV-2, the
284 renin-angiotensin-aldosterone (RAS) system is supposed to over-activate in response to
285 COVID-19. The RAS system was less studied in thyroid carcinomas. A clinical study

286 revealed a significantly increased expression of ACE2 in cancer tissues in comparison with
287 benign nodules (49). The result suggested that the RAS system might involve in tumor
288 progression, as supported in previous basic research (50). However, direct and solid evidences
289 are lacking in the relationship between AGT and thyroid cancers.

290 KNG1 is an essential factor in the kallikrein-kinin system and plays an important role in
291 blood coagulation. The over expression of KNG1 could inhibit proliferation and induce
292 apoptosis of glioma cells (51). Its anticancer mechanisms include the induction of G1 phase
293 cell cycle, the activation of caspase 3 and 9 and the inhibition of vascular endothelial growth
294 factor expression. Of interest, the expression of KNG1 was increased in colorectal cancers (52,
295 53). The phenomenon could be explained by the compensative effect of cancer tissues. In
296 patients with COVID-19, KNG1 was shown to be upregulated in circulation together with
297 other regulators of coagulation (plasminogen, fibronectin 1, etc.) (54), suggesting that
298 coagulation dysfunction might occur.

299 Lipid and cholesterol metabolism and transport are biological processes most likely involved
300 in the common pathogenic mechanism of COVID-19 and DTC. Schmelter *et al.* collected 482
301 serum samples from infected patients and healthy volunteers and tested the serum lipid profile.
302 They discovered that very-low-density lipoprotein, intermediate-density lipoprotein particles
303 and associated apolipoprotein B were significantly elevated in patients with SARS-CoV-2
304 infection, whereas cholesterol and APOA2 were decreased (55). In another study using the
305 proteomic approach with 41 patients, APOM in high-density lipoprotein was inversely
306 associated with the odds of death due to COVID-19 complications (56). Since numerous
307 studies have reported dyslipidemia due to COVID-19, recent researches uncovered the
308 underlying mechanisms. When SARS-CoV-2 enters the host cell via the receptor ACE2,
309 cholesterol is essential for the formation of syncytia (57). This might help to explain the
310 success of lipid apheresis as the treatment for patients with long-COVID syndromes (58).
311 Previous studies have proved that dyslipidemia, especially hyperlipidemia and
312 hypercholesterolemia, could increase the risk of various cancers (59, 60). Excess lipid and
313 cholesterol would increase intracellular oxidative stress and consequently promote
314 carcinogenesis and aggressiveness (61). Evidence has shown that lipid metabolism was
315 impaired in those individuals with long-COVID-19 (62), we could postulate that dyslipidemia
316 due to post-acute sequelae of COVID-19 might elevate the risk of thyroid cancer in a long
317 term.

318 The associations between other hub genes and COVID-19 and DTC were also studied. C3
319 encodes for complement component 3. The complement system can be activated by several
320 different mechanisms in acute inflammation and malignancies. The clinical studies of C3 in
321 COVID-19 are controversial. Some reports favored that decreased C3 levels were associated
322 with the disease severity (63, 64), while another research found no statistical significance (65).
323 A clinical study evaluated the proteomic profile in fine needle aspiration biopsy (66). C3
324 expression was discovered to decrease in PTC tissues, which could activate the downstream
325 complement system and exert a compensative anticancer effect. Similar to this article, GC
326 expression was also altered in our study. A previous research observed a decreased GC in
327 PTC tissue was related to enhanced tumor proliferation and migration (67). The link between
328 COVID-19 and GC is unclear currently. A commentary postulated that GC might play a role
329 in vitamin D deficiency in infected patients (68). Besides, TF, an iron-related serum protein

330 associated with chronic inflammation, was proved to be indicative of the severity and
331 coagulative state in COVID-19 patients (69-71). However, the association between TF and
332 DTC, if exists, was unknown. Of the rest five hub genes, the levels of AHSG, ITIH2 and
333 SERPINA1 were found to be the predictors of severity in patients with SARS-CoV-2
334 infection (72-74). Besides, the expressions of AHSG, SERPINA1 and TTR were altered in
335 PTCs (75-77). Of note, the above researches utilized omics methods to evaluate the
336 expression profiles but the underlying mechanisms between molecules and diseases were not
337 explored. The roles of SERPINC1 in COVID-19 and thyroid cancer have not been studied.

338 One letter published in Sept 2022 conducted a bioinformatic analysis similar to our study
339 (78). In this study, a database from iProX was analyzed for the identification of DEPs. The
340 transcription profiles of thyroid cancers and normal controls were downloaded from the data
341 from the Cancer Genome Atlas (TCGA) database. Using a different algorithm and criteria
342 ($p < 0.05$, $\log_2|FC| > 1$), this research identified ten more DEPs for COVID-19-infected thyroid
343 tissues (137 in our study and 147 in this study). Besides, 31 differentially expressed genes
344 were determined with 568 TCGA samples. However, only one common gene/protein
345 (coagulation factor XII) was identified with the Venn diagram. This pilot research has some
346 defects in the study design. First, samples in TCGA databases were collected from different
347 sources and batches. The batch effects between arrays were not normalized before analysis.
348 Second, differential expression analysis was conducted on both mRNA and protein levels.
349 Altered mRNA expressions do not certainly indicate the changes of translation, and vice versa.
350 Finally, the GO annotations and pathway enrichment analysis were not conducted, which
351 limited the generalization of conclusions.

352 There are some limitations in our study. First, due to the lack of patients with concomitant
353 thyroid cancer and COVID-19, the results of our study were not validated in human samples.
354 Second, we identified some novel molecules associated with SARS-CoV-2 infection or DTC,
355 the underlying mechanisms were not evaluated with *in vitro* or *in vivo* experiments. Besides,
356 only 30 samples were extracted and analyzed in the matrix of COVID-19. The sample size
357 was relatively small.

358 In conclusion, our study identified twelve hub genes from 49 common DEPs. GO
359 annotations and pathway enrichment analysis focused on lipid and cholesterol metabolism
360 and transport, followed by vasodilation and coagulation process. The common pathogenic
361 mechanisms suggest the infection of SARS-CoV-2 might exert adverse effects on patients
362 with DTCs. Further clinical and basic researches are needed to verify our conclusions.

363

364

365 **Abbreviations**

366 ACE2, angiotensin-converting enzyme 2; AGT, angiotensinogen; AHSG, alpha 2-Heremans
367 Schmidt glycoprotein; APOA2, apolipoprotein A2; APOM, apolipoprotein M; AUC, the area
368 under the curve; BP, biological process; C3, complement C3; CC, cellular component;
369 COIVD-19, coronavirus disease 2019; CTD, Comparative Toxicogenomics Database; DEP,
370 differentially expressed protein; DTC, differentiated thyroid cancer; EBV, Epstein-Barr virus;
371 FC, fold change; FE, fold enrichment; FTC, follicular thyroid cancer; GC, vitamin D binding
372 protein; GO, Gene Ontology; ITIH2, inter-alpha-trypsin inhibitor heavy chain 2; KEGG,
373 Kyoto Encyclopedia of Genes and Genome; KNG1, kininogen 1; MF, molecular function; NT,
374 normal thyroid tissues; PPI, protein-protein interaction; PTC, papillary thyroid cancer; RAS,
375 renin-angiotensin-aldosterone; ROC, receiver operator characteristics; SARS-CoV-2, severe
376 acute respiratory syndrome coronavirus 2; SERPINA1, serpin family A member 1;
377 SERPINC1, serpin family C member 1; TCGA, the Cancer Genome Atlas; TF, transferrin;
378 TriC/CCT, T-complex protein 1 ring complex/chaperonin-containing T-complex protein 1;
379 TTR, transthyretin;
380

381 **Disclosures**

382 Conflicts of interest

383 The authors declare no conflict of interest.

384

385 Authors contribution

386 Conceptualization: HQ. Liu & C. Chen

387 Methodology: HQ. Liu, JX. Wang & C. Chen

388 Formal analysis: HQ. Liu, JX. Wang & D. Yang

389 Investigation: HQ. Liu, JX. Wang & D. Yang

390 Writing – original draft preparation: HQ. Liu & JX. Wang

391 Writing – review and editing: D. Yang & C. Chen

392 Supervision: C. Chen

393 Funding acquisition: C. Chen

394

395 Acknowledgments

396 We wish to thank researchers who provide the two proteomic profiles.

397

398 Funding

399 This research was supported by the grants from Beijing Xisike Clinical Oncology Research

400 Foundation (Y-SY201901-0189), the Fundamental Research Funds for the Central

401 Universities (2042019kf0229), the Science and Technology Major Project of Hubei Province

402 (Next-Generation AI Technologies) (2019AEA170).

403

404 Data availability

405 The two proteomic profiles can be downloaded from iProx database (IPX0001444000 &

406 IPX0002393000). Supplementary figures and data files were deposited in Mendeley database

407 (DOI: 10.17632/5cg2dmz5nb.2).

408

409 **References**

- 410 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *Ca-a Cancer Journal for*
411 *Clinicians*. 2022;72(1):7-33.
- 412 2. Guay B, Johnson-Obaseki S, McDonald JT, Connell C, Corsten M. Incidence of Differentiated
413 Thyroid Cancer by Socioeconomic Status and Urban Residence: Canada 1991-2006. *Thyroid*.
414 2014;24(3):552-5.
- 415 3. Yan KL, Li S, Tseng C-H, Kim J, Nguyen DT, Dawood NB, et al. Rising Incidence and
416 Incidence-Based Mortality of Thyroid Cancer in California, 2000-2017. *Journal of Clinical*
417 *Endocrinology & Metabolism*. 2020;105(6):1770-7.
- 418 4. Banerjee M, Wiebel JL, Guo C, Gay B, Haymart MR. Use of imaging tests after primary
419 treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating
420 death and recurrence. *British Medical Journal*. 2016;354:i3839.
- 421 5. Davies L, Hoang JK. Thyroid cancer in the USA: current trends and outstanding questions. *Lancet*
422 *Diabetes & Endocrinology*. 2021;9(1):11-2.
- 423 6. Li Q, Li X, Sun J, Di W, Zhang L. The relationship between the thyroid carcinoma and
424 epstein-barr virus infection. *Chinese Journal of Experimental Surgery*. 2014;31(3):627-9.
- 425 7. Moghoofei M, Mostafaei S, Nesaei A, Etemadi A, Nahand JS, Mirzaei H, et al. Epstein-Barr virus
426 and thyroid cancer: The role of viral expressed proteins. *Journal of Cellular Physiology*.
427 2019;234(4):3790-9.
- 428 8. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Barani L, et al. Thyroid cancer in
429 HCV-related chronic hepatitis patients: A case-control study. *Thyroid*. 2007;17(5):447-51.
- 430 9. An J, Kim JW, Shim JH, Han S, Yu CS, Choe J, et al. Chronic hepatitis B infection and
431 non-hepatocellular cancers: A hospital registry-based, case-control study. *Plos One*.
432 2018;13(3):e0193232.
- 433 10. Hong CY, Sinn DH, Kang D, Paik SW, Guallar E, Cho J, et al. Incidence of extrahepatic cancers
434 among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. *Journal of*
435 *Viral Hepatitis*. 2020;27(9):896-903.
- 436 11. Wang JH, Zhang WP, Liu HX, Wang D, Li YF, Wang WQ, et al. Detection of human parvovirus
437 B19 in papillary thyroid carcinoma. *British Journal of Cancer*. 2008;98(3):611-8.
- 438 12. Adamson LA, Fowler LJ, Clare-Salzler MJ, Hobbs JA. Parvovirus B19 Infection in Hashimoto's
439 Thyroiditis, Papillary Thyroid Carcinoma, and Anaplastic Thyroid Carcinoma. *Thyroid*.
440 2011;21(4):411-7.
- 441 13. Tsai JH, Tsai CH, Cheng MH, Lin SJ, Xu FL, Yang CC. Association of viral factors with
442 non-familial breast cancer in Taiwan by comparison with non-cancerous, fibroadenoma, and thyroid
443 tumor tissues. *Journal of Medical Virology*. 2005;75(2):276-81.
- 444 14. Arisawa K, Soda M, Akahoshi M, Fujiwara S, Uemura H, Hiyoshi M, et al. Human T-cell
445 lymphotropic virus type-1 infection and risk of cancer: 15.4 year longitudinal study among atomic
446 bomb survivors in Nagasaki, Japan. *Cancer Science*. 2006;97(6):535-9.
- 447 15. Hobbs JA, Adamson-Small LA. Parvovirus and Thyroid Cancer. *Seminars in Oncology*.
448 2015;42(2):304-8.
- 449 16. Worldometer. Countries where COVID-19 has spread 2022 [Available from:
450 <https://www.worldometers.info/coronavirus/countries-where-coronavirus-has-spread/?rel=outbound>.

- 451 17. Chen K, Jiang S, Hu A. Research progress on the mechanism of multiple organ dysfunction in
452 patients with COVID-19. *Chinese Journal of Clinical Infectious Diseases*. 2021;14(2):102-6.
- 453 18. Mitsuyama K, Tsuruta K, Takedatsu H, Yoshioka S, Morita M, Niwa M, et al. Clinical Features
454 and Pathogenic Mechanisms of Gastrointestinal Injury in COVID-19. *Journal of Clinical Medicine*.
455 2020;9(11):3630.
- 456 19. Chegini R, Mojtahedi Z, Lakkakula BVKS, Pezeshgi A, Niazi S, Nasri H. COVID-19 and the
457 kidney; mechanisms of tubular injury by SARS-CoV-2. *Journal of Renal Injury Prevention*.
458 2021;10(1):e08.
- 459 20. Yi J, Miao J, Zuo Q, Owusu F, Dong Q, Lin P, et al. COVID-19 pandemic: A multidisciplinary
460 perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological
461 responses. *Frontiers in Immunology*. 2022;13:978619.
- 462 21. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, In GK, et al. COVID-19 Outcomes
463 of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. *Endocrine
464 Practice*. 2021;27(2):90-4.
- 465 22. Liu HQ, Zhan L, Guo LT, Yu XZ, Li LR, Feng HF, et al. More Aggressive Cancer Behaviour in
466 Thyroid Cancer Patients in the Post-COVID-19 Pandemic Era: A Retrospective Study. *International
467 Journal of General Medicine*. 2021;14:7197-206.
- 468 23. Duntas LH, Jonklaas J. COVID-19 and Thyroid Diseases: A Bidirectional Impact. *Journal of the
469 Endocrine Society*. 2021;5(8):bvab076.
- 470 24. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid
471 gland: an update. *Reviews in endocrine & metabolic disorders*. 2021;22(4):803-15.
- 472 25. Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a
473 wide variety of human tissues. *Infectious Diseases of Poverty*. 2020;9(1):45.
- 474 26. Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource.
475 *Nucleic Acids Research*. 2019;47(D1):D1211-D7.
- 476 27. Nie X, Qian L, Sun R, Huang B, Dong X, Xiao Q, et al. Multi-organ proteomic landscape of
477 COVID-19 autopsies. *Cell*. 2021;184(3):775-91.e14.
- 478 28. Sun Y, Selvarajan S, Zang Z, Liu W, Zhu Y, Zhang H, et al. Artificial intelligence defines
479 protein-based classification of thyroid nodules. *Cell Discovery*. 2022;8(1):85.
- 480 29. Bateman A, Martin M-J, Orchard S, Magrane M, Agivetova R, Ahmad S, et al. UniProt: the
481 universal protein knowledgebase in 2021. *Nucleic Acids Research*. 2021;49(D1):D480-D9.
- 482 30. Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P, et al. Sangerbox: A comprehensive,
483 interaction-friendly clinical bioinformatics analysis platform. *iMeta*. 2022;1(3):e36.
- 484 31. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S. AmiGO: online access to ontology
485 and annotation data. *Bioinformatics*. 2009;25(2):288-9.
- 486 32. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists
487 using DAVID bioinformatics resources. *Nature Protocols*. 2009;4(1):44-57.
- 488 33. Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, et al. The reactome
489 pathway knowledgebase 2022. *Nucleic Acids Research*. 2022;50(D1):D687-D92.
- 490 34. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database
491 in 2021: customizable protein-protein networks, and functional characterization of user-uploaded
492 gene/measurement sets. *Nucleic Acids Research*. 2021;49(D1):D605-D12.
- 493 35. Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects
494 and sub-networks from complex interactome. *Bmc Systems Biology*. 2014;8:S11.

- 495 36. Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader GD, et al. GeneMANIA update
496 2018. *Nucleic Acids Research*. 2018;46(W1):W60-W4.
- 497 37. Davis AP, Grondin CJ, Johnson RJ, Sciaky D, Wieggers J, Wieggers TC, et al. Comparative
498 Toxicogenomics Database (CTD): update 2021. *Nucleic Acids Research*. 2021;49(D1):D1138-D43.
- 499 38. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased
500 patients with coronavirus disease 2019: retrospective study. *British Medical Journal*. 2020;368:m1091.
- 501 39. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of
502 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*.
503 2020;395(10224):565-74.
- 504 40. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G, et al. Thyrotoxicosis in
505 patients with COVID-19: the THYRCOV study. *European Journal of Endocrinology*.
506 2020;183(4):381-7.
- 507 41. Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A, et al.
508 SARS-CoV-2-related atypical thyroiditis. *Lancet Diabetes & Endocrinology*. 2020;8(9):739-41.
- 509 42. Jimenez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves'
510 hyperthyroidism? *Journal of Endocrinological Investigation*. 2021;44(2):387-8.
- 511 43. Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of
512 two cases of Graves' disease after COVID-19. *Journal of Endocrinological Investigation*.
513 2020;43(10):1527-8.
- 514 44. Sahin M, Haymana C, Demirci I, Tasci I, Rifat E, Unluturk U, et al. The clinical outcomes of
515 COVID-19 infection in patients with a history of thyroid cancer: A nationwide study. *Clinical*
516 *Endocrinology*. 2021;95(4):628-37.
- 517 45. Chai C, Feng X, Lu M, Li S, Chen K, Wang H, et al. One-year mortality and consequences of
518 COVID-19 in cancer patients: A cohort study. *Iubmb Life*. 2021;73(10):1244-56.
- 519 46. Cafiero C, Rosapepe F, Palmirota R, Re A, Ottaiano MP, Benincasa G, et al. Angiotensin System
520 Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and
521 Asymptomatic Patients: A Pilot Study. *Pharmacogenomics & Personalized Medicine*. 2021;14:621-9.
- 522 47. Kouhpayeh HR, Tabasi F, Dehvari M, Naderi M, Bahari G, Khalili T, et al. Association between
523 angiotensinogen (AGT), angiotensin-converting enzyme (ACE) and angiotensin-II receptor 1 (AGTR1)
524 polymorphisms and COVID-19 infection in the southeast of Iran: a preliminary case-control study.
525 *Translational medicine communications*. 2021;6(1):26.
- 526 48. Tepasse P-R, Vollenberg R, Steinebrey N, Koenig S. The Dysregulation of the Renin-Angiotensin
527 System in COVID-19 Studied by Serum Proteomics: Angiotensinogen Increases with Disease Severity.
528 *Molecules*. 2022;27(8):2495.
- 529 49. Narayan SS, Lorenz K, Ukkat J, Hoang-Vu C, Trojanowicz B. Angiotensin converting enzymes
530 ACE and ACE2 in thyroid cancer progression. *Neoplasma*. 2020;67(2):402-9.
- 531 50. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, et al. Role of host angiotensin
532 II type 1 receptor in tumor angiogenesis and growth. *Journal of Clinical Investigation*.
533 2003;112(1):67-75.
- 534 51. Xu J, Fang J, Cheng Z, Fan L, Hu W, Zhou F, et al. Overexpression of the Kininogen-1 inhibits
535 proliferation and induces apoptosis of glioma cells. *Journal of Experimental & Clinical Cancer*
536 *Research*. 2018;37:180.
- 537 52. Quesada-Calvo F, Massot C, Bertrand V, Longuespee R, Bletard N, Somja J, et al. OLFM4,
538 KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early

- 539 colorectal cancer stages. *Clinical Proteomics*. 2017;14:9.
- 540 53. Lin L, Zeng X, Liang S, Wang Y, Dai X, Sun Y, et al. Construction of a co-expression network
541 and prediction of metastasis markers in colorectal cancer patients with liver metastasis. *Journal of*
542 *Gastrointestinal Oncology*. 2022;13(5):2426-38.
- 543 54. Geyer PE, Arend FM, Doll S, Louiset M-L, Winter SV, Mueller-Reif JB, et al. High-resolution
544 serum proteome trajectories in COVID-19 reveal patient-specific seroconversion. *Embo Molecular*
545 *Medicine*. 2021;13(8):e14167.
- 546 55. Schmelter F, Foeh B, Mallagaray A, Rahmoeller J, Ehlers M, Lehrian S, et al. Metabolic and
547 Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients.
548 *Frontiers in Molecular Biosciences*. 2021;8:737039.
- 549 56. Souza Junior DR, Martins Silva AR, Rosa-Fernandes L, Reis LR, Alexandria G, Bhosale SD, et al.
550 HDL proteome remodeling associates with COVID-19 severity. *Journal of Clinical Lipidology*.
551 2021;15(6):796-804.
- 552 57. Sanders DW, Jumper CC, Ackerman PJ, Bracha D, Donlic A, Kim H, et al. SARS-CoV-2 requires
553 cholesterol for viral entry and pathological syncytia formation. *Elife*. 2021;10:e65962.
- 554 58. Bornstein SR, Voit-Bak K, Donate T, Rodionov RN, Gainetdinov RR, Tselmin S, et al. Chronic
555 post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?
556 *Molecular Psychiatry*. 2022;27(1):34-7.
- 557 59. Moon H, Ruelcke JE, Choi E, Sharpe LJ, Nassar ZD, Bielefeldt-Ohmann H, et al. Diet-induced
558 hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and
559 caveolin-1. *Oncotarget*. 2015;6(10):7438-53.
- 560 60. Shen Y, Wang C, Ren Y, Ye J. A comprehensive look at the role of hyperlipidemia in promoting
561 colorectal cancer liver metastasis. *Journal of Cancer*. 2018;9(16):2981-6.
- 562 61. Revilla G, de Pablo Pons M, Baila-Rueda L, Garcia-Leon A, Santos D, Cenarro A, et al.
563 Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness. *Sci Rep*.
564 2019;9:10260.
- 565 62. Guntur VP, Nemkov T, de Boer E, Mohning MP, Baraghoshi D, Cendali FI, et al. Signatures of
566 Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute
567 Sequelae of COVID-19 (PASC). *Metabolites*. 2022;12(11):1026.
- 568 63. Fang S, Wang H, Lu L, Jia Y, Xia Z. Decreased complement C3 levels are associated with poor
569 prognosis in patients with COVID-19: A retrospective cohort study. *International*
570 *immunopharmacology*. 2020;89(Pt A):107070.
- 571 64. Jiang H, Chen Q, Zheng S, Guo C, Luo J, Wang H, et al. Association of Complement C3 with
572 Clinical Deterioration Among Hospitalized Patients with COVID-19. *International Journal of General*
573 *Medicine*. 2022;15:849-57.
- 574 65. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in
575 Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clinical infectious diseases*.
576 2020;71(15):762-8.
- 577 66. Yekta RF, Oskouie AA, Tavirani MR, Mohajeri-Tehrani MR, Soroush AR. Decreased
578 apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid
579 carcinoma: A proteomic study. *International Journal of Biological Markers*. 2018;33(4):455-62.
- 580 67. Mull B, Davis R, Munir I, Perez MC, Simental AA, Khan S. Differential expression of Vitamin D
581 binding protein in thyroid cancer health disparities. *Oncotarget*. 2021;12(7):596-607.
- 582 68. Speeckaert MM, Speeckaert R, Delanghe JR. Vitamin D binding protein in COVID-19. *Clinical*

- 583 Medicine. 2020;20(5):E136-E7.
- 584 69. McLaughlin K-M, Bechtel M, Bojkova D, Muench C, Ciesek S, Wass MN, et al.
585 COVID-19-Related Coagulopathy-Is Transferrin a Missing Link? *Diagnostics*. 2020;10(8):539.
- 586 70. Suriawinata E, Mehta KJ. Iron and iron-related proteins in COVID-19. *Clinical and Experimental*
587 *Medicine*. 2022;18:1-23.
- 588 71. Yadav D, Pvsn KK, Tomo S, Sankanagoudar S, Charan J, Purohit A, et al. Association of
589 iron-related biomarkers with severity and mortality in COVID-19 patients. *Journal of Trace Elements*
590 *in Medicine and Biology*. 2022;74:127075.
- 591 72. Vollmy F, van den Toorn H, Chiozzi RZ, Zucchetti O, Papi A, Volta CA, et al. A serum proteome
592 signature to predict mortality in severe COVID-19 patients. *Life Science Alliance*.
593 2021;4(9):e202101099.
- 594 73. Upadhyai P, Shenoy PU, Banjan B, Albeshr MF, Mahboob S, Manzoor I, et al. Exome-Wide
595 Association Study Reveals Host Genetic Variants Likely Associated with the Severity of COVID-19 in
596 Patients of European Ancestry. *Life*. 2022;12(9):1300.
- 597 74. Zheng J, Zhang Y, Zhao H, Liu Y, Baird D, Karim MA, et al. Multi-ancestry Mendelian
598 randomization of omics traits revealing drug targets of COVID-19 severity. *Ebiomedicine*.
599 2022;81:104112.
- 600 75. Abdullah MI, Lee CC, Junit SM, Ng KL, Hashim OH. Tissue and serum samples of patients with
601 papillary thyroid cancer with and without benign background demonstrate different altered expression
602 of proteins. *Peerj*. 2016;4:e2450.
- 603 76. Giusti L, Iacconi P, Ciregia F, Giannaccini G, Donatini GL, Basolo F, et al. Fine-needle aspiration
604 of thyroid nodules: Proteomic analysis to identify cancer biomarkers. *Journal of Proteome Research*.
605 2008;7(9):4079-88.
- 606 77. Qu T, Li Y-P, Li X-H, Chen Y. Identification of potential biomarkers and drugs for papillary
607 thyroid cancer based on gene expression profile analysis. *Molecular medicine reports*.
608 2016;14(6):5041-8.
- 609 78. Deng J, Cai X, Chen Z. The putative mechanistic insights on how SARS-CoV-2 might influence
610 the outcomes in cancer patients. *Experimental Hematology & Oncology*. 2022;11(1):52.
- 611

612 **Table**

613 Table 1. The summary of the included datasets.

Series number	Organism	Sample type	Diseases	Release date	Number of samples (used/total)	Groups
IPX0001444000	Human	FFPE, FNAB	PTC, FTC, benign thyroid diseases, normal thyroid tissues	Sept 6, 2022	223/1161 ^a	FTC/PTC/normal: 64/119/40
IPX0002393000	Human	FFPE	COVID-19, normal thyroid tissues	Dec 11, 2020	30/218	COVID-19/normal: 15/15

614
615 Note: The two datasets were provided by Westlake laboratory of life sciences and biomedicine, key laboratory of structural biology of Zhejiang province,
616 school of life sciences, Westlake University.

617 Abbreviations: COVID-19, coronavirus disease 2019; FFPE, formalin-fixed paraffin-embedded tissue; FNAB, fine-needle aspiration biopsy; FTC, follicular
618 thyroid cancer; PTC, papillary thyroid cancer

619 ^a A total of 1133 patients were involved in the dataset. More than one samples could be collected from different nodules of one patient.

620

621 **Figure legends**

622 Figure 1. The flow chart of the study.

623 Abbreviations: COVID-19, coronavirus disease 2019; DEP, differentially expressed protein; DTC,
624 differentiated thyroid cancer; NT normal thyroid tissue.

625

626 Figure 2. The volcano map of DEPs in two comparisons, (a) COVID-19 vs. not infected, and (b) DTC
627 vs. NT. (c). The Venn diagram of DEPs from two expression matrices.

628 Note: The three DEPs with lowest p -value were displayed in the figure.

629 Abbreviations: NT, normal thyroid tissue; DTC, differentiated thyroid cancer.

630

631 Figure 3. The bubble charts of gene ontology. (a) biological process, (b) cellular component, and (c)
632 molecular function. (d). The results of pathway enrichment analysis.

633 Note: Pathways with p -value < 0.001 were displayed in the chart, while other pathways could be found
634 in the Supplementary data.

635

636 Figure 4. The protein-protein interaction network of shared DEPs.

637 Note: Redder color indicates higher connectivity of the gene with other genes. Disconnected nodes
638 were removed from the diagram.

639

640 Figure 5. (a) The 12 intersected hub genes identified with the eight algorithms in CytoHubba. (b) The
641 co-expression map of 12 hub genes and their related genes.

642 Twelve hub genes were displayed in the inner circle while the related genes were in the outer circle.

643 Abbreviations: EPC, edge percolated component; MCC, maximal clique centrality; MNC, maximum
644 neighborhood component.

645

646 Figure 6. The ROC curve of 12 hub genes in diagnosis of (a) COVID-19 and (b) DTC.

647

648 Figure 7. The associations of hub genes and COVID-19 and DTC

649 * Direct evidence has been revealed between AGT and COVID-19.

DEPs in IPX0001444000:
DTC vs. NT

DEPs in IPX0002393000:
COVID-19 vs. Not infected

Shared DEPs

Gene ontology

Pathway enrichment analysis

Protein-protein interaction network construction




Hub gene identification





Gene ontology


Pathway enrichment analysis

Diagnostic performance
of hub genes




Associations between
hub genes and diseases



(a)**(b)****(c)****(d)**



(a)



(b)

